Business Context and Reporting Period
Company: iSpecimen Inc. (ISPC)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2026
Business Overview: iSpecimen operates a proprietary online marketplace connecting medical researchers with hospitals and laboratories to procure human biospecimens (biofluids, tissues, cells). The company operates as a single reporting segment.
Corporate Actions: The company executed a 1-for-40 reverse stock split effective April 27, 2026, to maintain Nasdaq listing compliance. All share data in this report is adjusted retroactively.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Revenue | $307,949 | $1,770,645 |
| Net Loss | $(3,638,032) | $(2,705,639) |
| Loss Per Share (Basic & Diluted) | $(4.18) | $(44.90) |
| Cash and Cash Equivalents (End of Period) | $4,414,364 | $588,775 |
| Working Capital | $(992,538) (Deficit) | $723,284 |
| Total Assets | $7,393,201 | $9,531,410 |
| Total Liabilities | $5,656,821 | $6,443,179 |
| Accumulated Deficit | $(85,988,181) | $(74,568,256) |
Cash Flow Summary (Six Months Ended June 30, 2026):
- Operating Activities: $(4,051,471) used
- Investing Activities: $(700,000) used (primarily capitalization of internally developed software)
- Financing Activities: $2,285,000 provided (net proceeds from private placement)
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 83% year-over-year to $307,949. This was driven by a 75% decrease in specimen count (from 4,842 to 1,225) and a 31% decrease in average selling price per specimen.
- Expense Volatility:
- Sales & Marketing: Increased 245% to $2,086,762, primarily due to a $1.97 million increase in advertising and promotion expenses.
- Technology: Decreased 49% to $554,883, driven by lower amortization and payroll, despite $700,000 in new software capitalization.
- General & Administrative: Decreased 35% to $1,105,818 due to reduced compensation and professional fees.
- Liquidity Position: The company moved from a positive working capital position in 2025 to a deficit of approximately $993,000 in 2026. Cash balances increased significantly due to financing activities, offsetting operating cash burn.
- Other Income: Total other income decreased 65% to $263,356, largely due to a reduction in "other income" items compared to the prior year.
Guidance, Outlook, Risks, and Contingencies
Going Concern Uncertainty
Management has concluded that substantial doubt exists regarding the company's ability to continue as a going concern for one year from the filing date. This is due to recurring losses, an accumulated deficit of nearly $86 million, and negative working capital. Management's plan to mitigate this includes generating additional revenue, deferring capital expenditures, and raising additional capital. However, these plans are not considered probable.
Management Commentary & Strategy
- Cost Reduction: The company continues to right-size operations. Workforce reductions since 2024 have reduced monthly compensation costs by approximately 67% compared to 2024 levels.
- Technology Investment: Despite cost cuts, technology costs increased 450% year-over-year due to the development and launch of a new AI-powered platform and marketplace modernization.
- Sales Strategy: The company is shifting to an account-based sales approach and focusing on high-value suppliers to improve conversion ratios.
Legal Proceedings & Contingencies
- Focus Technology Solutions: Pending litigation regarding non-payment for IT services. The company is required to deposit 15% of net revenue into escrow (up to $420,000) as pre-judgment security. The company asserts counterclaims for service disruption damages.
- Azenta US, Inc.: Claim for $651,262 regarding breach of contract. The company has offered $125,000 to settle; no response received.
- Krisbio, LLC: Claim for $266,380 regarding a Participation Agreement. Discovery has not yet begun.
- Sales Tax Liability: As of June 30, 2026, the company has an accrued sales tax liability of approximately $233,000 plus $55,000 in interest and penalties. The company is actively collecting past taxes from non-exempt customers.
Internal Controls
Management identified a material weakness in internal controls over financial reporting related to the design and maintenance of controls for sales tax calculation, collection, and remittance. A remediation plan is ongoing.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $4.4 million cash balance against the current monthly burn rate, given the "substantial doubt" going concern warning.
- Revenue Quality: Assess the sustainability of the 83% revenue decline and the concentration risk (one customer accounted for 28.37% of revenue in the six months ended June 30, 2026).
- Legal Exposure: Monitor the status of the Focus Technology Solutions litigation and the potential impact of the 15% revenue escrow requirement on liquidity.
- Sales Tax Resolution: Track the progress of collecting the $233,000 sales tax liability from customers and the effectiveness of the new tax software implementation.
- Capital Raising: Review the terms and success of the subsequent August 2026 public offering (Note 12) intended to repay liabilities and fund operations.